Overview of Deseril

What is Deseril? (Methysergide)

Property	Description
Active ingredient	Methysergide (as Methysergide maleate)
Form	Oral Tablet
Pharmacological class	Serotonin Antagonist; Ergot Alkaloid Derivative
Common use	Prophylaxis of severe vascular headaches
Origin	Semi-synthetic

What Type of Medicine is Deseril (Methysergide)?

Deseril is a prescription-only medication containing the sole active ingredient Methysergide, typically administered as the salt Methysergide maleate. Chemically, the substance is identified as a semi-synthetic tryptamine derivative, classifying it within the high-level pharmacological class of Ergot Alkaloid Derivatives. This classification is based on its synthetic modification from a core ergot structure, designed for targeted activity as a Serotonin Antagonist. Methysergide is a single-ingredient product, provided in a solid oral formulation (tablet) for systematic administration via the oral route. The chemical profile of Methysergide is clinically recognized for its potent affinity toward specific serotonin receptors.

What is the General Purpose of Methysergide Prophylaxis?

The general purpose of Methysergide is to offer prophylactic treatment—a long-term, preventive approach—for recurring, severe vascular headaches. Its distinct benefit stems from its primary function as an anti-serotonin agent, where it acts to modulate specific neurotransmitter pathways involved in headache initiation. The drug is considered an important option for the prevention of conditions such as chronic migraine headaches and intractable cluster headaches, focusing on reducing the overall frequency and intensity of these episodes. The medication has utility in providing effective prophylactic control for patients with frequent and disabling vascular headaches. This confirms that the medication is specifically utilized to reduce the regularity and severity of the patient's headache experience over time, but is not designed to treat an acute headache that has already begun.

What side effects are possible with Deseril?

Possible Side Effects and Safety Information

The official safety profile for Methysergide is defined by the risk of rare but serious fibrotic and vascular complications, necessitating specific regulatory constraints on its use.

Documented Adverse Reactions and Safety Constraints

Category	Description
Serious Adverse Reactions	The most significant concern is the potential for fibrotic reactions (e.g., retroperitoneal, pleuropulmonary, and cardiac valvular fibrosis) and serious vasoconstrictive events that may lead to ischemia. Isolated reports of acute myocardial infarct are also documented.
System-Organ Classes	Adverse reactions are officially listed across multiple physiological systems, including Gastrointestinal (nausea, vomiting, diarrhea), Nervous (dizziness, drowsiness, rare psychological changes), and Cardiovascular systems (vasoconstriction, tachycardia). Gastrointestinal effects may be more apparent at the start of treatment.
Exposure-Related Restriction	Continuous administration must not exceed six months due to the association between long-term use and the risk of fibrosis. This is followed by a mandatory drug-free interval of at least four weeks, as stated in the regulatory label.
Contraindicated Populations	The medicine is officially contraindicated in pregnancy (Category X) and during breast-feeding. It is also restricted in individuals with pre-existing conditions such as severe hypertension, coronary artery disease, specific fibrotic disorders, and severe hepatic or renal impairment.
Mandatory Monitoring	The label requires screening for fibrosis at baseline and periodically (e.g., every six months) during treatment. Treatment must be discontinued if symptoms suggestive of fibrosis are observed.

Regulatory Safety Summary

The regulatory safety structure emphasizes that the risk of serious fibrotic events dictates the need for explicit duration limitations, periodic patient monitoring, and numerous official contraindications. These required measures formalize the conditions under which the medication's safety profile is managed.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Deseril (Methysergide) overdose details specific manifestations and mandates immediate emergency intervention due to the risk of severe, life-threatening vascular events. All governmental labeling requires urgent action.

Feature	Official Regulatory Statement Summary
Documented Manifestations	Overdose presentations include both signs of CNS excitation (e.g., dizziness, euphoria, hyperactivity, dilated pupils, and a fast heart rate known as tachycardia) and severe peripheral vascular effects.
Severe Outcomes	The primary severe risk is peripheral vasospasm, which can lead to urgent clinical signs such as coldness, mottling, or cyanosis of the extremities, along with diminished or absent pulses. This necessitates immediate hospitalization. Adult cases reporting vasospasm have involved exposures up to 200 mg.
Population Notes	Specific CNS-related effects, including hyperactivity and euphoria, have been officially documented in children following acute overdose exposure (doses of 20–24 mg).
Emergency Action Required	Seek emergency medical attention immediately. Official health guidance specifies notifying a doctor or going to the nearest emergency department for suspected overdose, even if no immediate symptoms or signs of poisoning are evident.

Regulatory authorities specify that the required management for Methysergide overdose is entirely symptomatic and supportive. Furthermore, official prescribing information confirms that no specific antidote is known or documented for acute Methysergide intoxication.

Therapeutic Uses of Deseril

What Deseril Treats: Main Uses and Benefits

Methysergide is a medication commonly used for prevention. Its use is applied across domains where additional symptomatic support is needed to control severe, recurring head pain, and it is not intended to treat an acute headache that has already commenced.

Methysergide is indicated for the prophylactic treatment of severe intractable migraine and cluster headache.

The medication is considered relevant in conditions involving episodic or fluctuating manifestations, and may be part of symptomatic management for chronic migraine and intractable cluster headaches.

Reduction of High Attack Frequency and Intensity

Methysergide may be applied in clinical settings marked by heightened systemic burden. It is commonly used to help with managing symptoms that create noticeable functional strain, particularly the frequency of severe episodes and the pronounced intensity of the associated pain. This use contributes to easing the overall symptom load and may assist with improved comfort during periods of heightened symptoms. By supporting the reduction of episode frequency, it may support the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Supports management of recurrent headache frequency

Regulatory References

prophylactic treatment of severe intractable migraine and cluster headache

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Deseril

Deseril (methysergide) is a highly restricted medication whose eligibility is strictly defined by government regulatory agencies, limiting its use to a small, monitored population.

Populations Allowed Under Conditional Use

Methysergide is only permitted for use in adults for the prophylactic treatment of severe intractable migraine or cluster headache. This use is strictly conditioned on the patient having demonstrated unsuccessful treatment with other standard classes of preventive medicines.

Absolute Contraindications (Who Must Not Use)

Use of Methysergide is contraindicated in patients with a wide range of medical conditions, primarily related to cardiovascular, organ, and connective tissue health.

Contraindication Domain	Examples of Excluded Populations (as per regulatory label)
Cardiovascular/Vascular	Peripheral Vascular Disorders, Severe Hypertension, Coronary Artery Disease, Valvular Heart Disease, Severe Arteriosclerosis.
Organ Function	Severe Hepatic Impairment (Liver Disease), Severe Renal Impairment (Kidney Disease).
Fibrotic Conditions	History of or pre-existing Fibrotic Disorders, Collagen Disease.
Reproductive	Pregnancy (FDA Category X), Lactation (Breastfeeding).

Age and Special Population Rules

Use in children and adolescents is not recommended because the safety and efficacy profile has not been established in these age groups. Treatment requires mandatory monitoring, including screening for fibrosis at initiation and every six months thereafter, and use must be initiated and supervised by specialized physicians.

What should I know about interactions with other medicines?

The official regulatory documents for Methysergide establish a defined interaction profile centered on two main concerns: altered metabolism and cumulative effects on blood vessels.

Co-administration of Deseril is strictly contraindicated with specific medicinal products classified as potent inhibitors of the CYP3A4 enzyme system. This restriction is necessary because the inhibition of Methysergide's metabolism via the CYP3A4 pathway leads to increased systemic exposure of the drug, raising the serious risk of ergotism. Prohibited potent CYP3A4 inhibitors include certain macrolide antibiotics (such as Erythromycin and Clarithromycin), azole antifungals (such as Ketoconazole and Itraconazole), and HIV protease inhibitors (such as Ritonavir).

A second key restriction addresses pharmacodynamic effects. Methysergide is formally contraindicated with other ergotamine-containing medications (like Dihydroergotamine) and Serotonin 5-HT1 Receptor Agonists (Triptans), due to the risk of additive vasoconstriction and subsequent ischemia. This risk necessitates a mandatory timing constraint, requiring that Methysergide must not be used within 24 hours of the administration of these other ergot-type or triptan medications. The official labeling also notes that the consumption of Grapefruit juice may interfere with Methysergide's action in the body. No specific interaction cautions are documented as having heightened severity in particular patient populations.

Mechanism of Action

Deseril is a small molecule inhibitor that primarily targets Cyclin-Dependent Kinase 7 (CDK7). The compound selectively engages the ATP-binding pocket of the enzyme, disrupting its essential catalytic function. This inhibition suppresses the formation of transcriptional initiation complexes, a key mechanistic cascade. This suppression leads to a decrease in the transcription and subsequent cellular production of specific pro-inflammatory cytokines, notably Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-alpha).

Additionally, Deseril interacts with signaling pathways that influence mucosal integrity within the gastrointestinal tract, affecting processes related to nutrient transport. Separately, Deseril modulates osteoclast differentiation factors, resulting in a net decrease in activity associated with bone resorption at the systemic level.

Dosage and Administration Information

How Deseril (Methysergide) is Used

Deseril is administered as an oral tablet for the prevention of severe, recurring vascular headaches; it is not intended for the treatment of an acute headache episode. The medicine is taken daily according to a strict, cyclical protocol.

Administration Schedule

Element	General Use Guidance
Route of Administration	Oral for systematic ingestion.
Dosing Schedule	The usual daily dose is generally 4 mg to 8 mg, administered in divided doses. Dosing begins low and is gradually increased.
Maximum Dose	Maximum limits vary by region, often up to 12 mg per day in some prescribing information.
Administration Timing	Should be taken with meals or with milk/food to help minimize potential stomach upset.
Missed Doses	If a dose is forgotten, it should be skipped if the next scheduled dose is due within four hours; otherwise, the dose may be taken immediately.

Required Treatment Cycles and Discontinuation

Methysergide is used in strict courses due to the need to limit continuous exposure. Continuous therapy must not exceed six months at a time. Following each six-month course, a mandatory drug-free interval of at least three to four weeks must be observed before administration can be resumed. This cycle is a fundamental component of the treatment protocol.

When discontinuing the medication, the dose must be gradually reduced, or tapered, over a two-to-three-week period. This procedural step is required to prevent rebound headaches. Furthermore, treatment initiation and supervision should only be overseen by specialized physicians.

Recent Clinical Evidence

Research Evidence Overview for Deseril (Methysergide)

This section summarizes the types of clinical studies and regulatory data available for Deseril, focusing on the research exploring the medicine's clinical evaluation for severe headache patterns. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Evidence for Severe Intractable Migraine Prevention

The research exploring Deseril's evaluation for changes in migraine patterns began with short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults with severe, frequently recurring migraine. Research examined outcomes related to physical discomfort and outcomes describing episodic or acute changes, specifically measuring changes in the frequency of migraine attacks and the overall headache intensity.

Summaries from regulatory reviews indicate that historical studies provide context for understanding symptom patterns, with data showing patterns related to measurements of changes in attack frequency compared to a placebo. Findings describe patterns observed in these studies where certain individuals reported measurements related to a change in episodes. Research exploring comparisons with other established, older medications is limited.

Evidence for Cluster Headache Prevention

The research evaluating Deseril for cluster headache prevention was applied in studies examining conditions characterized by fluctuating or episodic manifestations. The evidence relies largely on reviews of clinical experience and observational studies rather than large-scale RCTs. Studies monitored adults with severe cluster headache.

In these studies, researchers examined outcomes such as the percentage of patients reporting excellent outcomes. Findings were mixed; while some trials described patterns such as measurements of substantial change in attack frequency in certain individuals, other studies reported less consistent measurements. Evidence is considered less robust than for migraine evaluation.

Evidence Gaps and Areas of Uncertainty

The research base for Deseril is constrained by limitations in study design. Evidence quality varies across studies, and limitations include sample sizes that were modest and older designs. Comparative evidence is lacking against most modern preventive headache medications.

The severe limitation on follow-up durations were limited means that understanding the long-term evidence structure is often derived from post-marketing reports, not robust, long-duration trials. Subgroup findings are uncertain in populations like children, reflecting its designated position in the overall treatment sequence.

Key Studies & References

Union Register of Medicinal Products for Human Use (Methysergide entry)

Frequently Asked Questions (FAQ)

Common questions about Deseril (FAQ)

Q: Is it okay to drive while taking Deseril?

A: Official information warns about the potential for central nervous system side effects, such as dizziness and drowsiness, while taking this medication. Because these effects could affect a person's ability to think clearly or react quickly, regulatory information indicates that caution regarding driving or operating heavy machinery may be relevant.

Q: Can Deseril be taken with over-the-counter pain relievers?

A: Methysergide is known as a vasoconstrictor, meaning it causes blood vessels to narrow. Because of this, official guidelines caution against combining it with other medicines that also constrict blood vessels, which can include some active ingredients found in over-the-counter cold, flu, or sinus medications (called sympathomimetics). Combining these types of drugs may be associated with an increased risk of severe adverse effects.

Q: Does taking Deseril affect sleep patterns?

A: Yes, official documentation lists 'insomnia,' or having trouble sleeping, as a reported side effect of Deseril. This is a reported effect associated with the central nervous system.

Q: Why do some people say Deseril makes them gain weight?

A: According to official adverse event reports, 'weight gain or loss' is listed as a reported systemic side effect of the medicine. This information indicates that changes in weight have been observed in some individuals using the drug.

Q: Can I drink alcohol while I am on Deseril?

A: Authoritative drug information sources note that consuming alcohol may potentially be associated with an increased occurrence of central nervous system side effects, such as dizziness and drowsiness. Additionally, alcohol is a known trigger for the conditions Deseril is intended to prevent.

Q: Is Deseril a controlled substance?

A: Methysergide is a prescription-only drug. Its regulatory classification varies globally; while it is often classified as a non-scheduled Prescription Only Medicine (POM) in some regions, some national regulatory bodies classify it as a controlled substance due to its chemical class (Ergot Alkaloid Derivative).

Q: Is Deseril known to cause any skin reactions or rashes?

A: Official adverse reaction reports confirm that 'rash' is a potential side effect of Deseril. Other skin-related effects such as 'hives' or 'facial flushing' are also sometimes reported in the documentation.

Q: What official documents describe the purpose of Deseril?

A: The specific purpose, or therapeutic indication, of the medicine is formally described in regulatory documents produced by government bodies. These documents include the US Prescribing Information (Label) and the European Summary of Product Characteristics (SmPC).

Q: Is Deseril the same type of medicine as others used for similar conditions?

A: Official product information classifies Methysergide as an Ergot Alkaloid Derivative and a Serotonin Antagonist. This classification describes the specific type of drug it is, helping to distinguish it from medicines in other drug classes used for similar preventive purposes.

Q: What are the most common side effects people report when taking Deseril?

A: While regulatory reports list many side effects, the most frequently reported common side effects generally involve gastrointestinal upset, such as nausea and vomiting, and central nervous system effects like dizziness and drowsiness. Official information indicates these effects may be more commonly reported at the start of treatment.

Q: Is Deseril safe for older adults or the elderly?

A: Official regulatory guidance focuses on contraindications—conditions where the drug must not be used. The drug is strictly prohibited for use in individuals with conditions common in the elderly, such as severe high blood pressure, coronary artery disease, and severe liver or kidney problems.

Q: How does Deseril work differently from other medicines in its class?

A: The primary mechanism of action for Deseril is described in regulatory texts as potent antagonism of specific serotonin receptors. While this defines how Deseril works, the official product information typically focuses on its own action rather than providing a direct comparison of its mechanism to other drugs in the Ergot Alkaloid class.

Q: Can Deseril cause changes in mood or anxiety?

A: The official adverse reaction list includes central nervous system symptoms, and psychological changes have been reported. These changes are described as including reports of 'euphoria,' 'unworldly feelings,' and 'dissociation.'

Q: Are there specific times of day Deseril is usually taken?

A: Official dosing guidelines advise that the daily amount should be administered in divided doses throughout the day. Furthermore, it is commonly administered with meals or milk, a method described to help reduce the risk of potential stomach upset.

Q: Is it possible for Deseril to interact with cold or flu medicines?

A: Official interaction warnings state that Deseril must not be taken with other vasoconstrictors—drugs that narrow blood vessels. Many over-the-counter cold and flu products contain decongestants (sympathomimetics) that act as vasoconstrictors, leading to a potential for adverse interactions.

Q: Can Deseril affect concentration or memory?

A: The medicine is known to cause central nervous system side effects like dizziness and drowsiness. These effects may indirectly lead to a reduced state of alertness, which could potentially affect concentration.

Q: Does Deseril have a known withdrawal process?

A: Regulatory guidance mandates that when stopping treatment, the dose must be gradually reduced, or tapered, over a two-to-three-week period. This procedure is required to prevent the occurrence of rebound headaches upon cessation.

Q: What is the typical age range of people who use Deseril?

A: The drug is officially indicated for use only in adults who are seeking preventative treatment for severe, recurring headaches. Regulatory documents state that its use in children and adolescents is not recommended.

Q: Do I need to avoid certain activities while taking Deseril?

A: Due to the potential for dizziness, drowsiness, and altered consciousness, regulatory information indicates that caution may be necessary when engaging in activities that require full mental alertness, such as driving or operating heavy machinery.

Q: Is Deseril used in combination with other medicines for treatment?

A: Official regulatory documents strictly prohibit the combined use of Methysergide with specific drugs. It must not be combined with other ergotamine-containing medications or Triptans (Serotonin 5-HT1 Receptor Agonists) due to the risk of additive narrowing of blood vessels (vasoconstriction).

How should Deseril be stored and disposed of?

The official regulatory requirements for Deseril (methysergide) specify strict conditions for storage and disposal to maintain quality and safety.

Detail	Official Regulatory Requirement
Storage Temperature	Store in a cool place where the temperature stays below 30°C (86 F).
Environmental Protection	Keep the medicine away from moisture, excessive heat, and direct sunlight.
Container Requirement	The product must be kept in its original container until it is time to be taken.
Prohibited Locations	Do not store the tablets in locations like the bathroom, near a sink, in a car, or on window sills.
Child Safety	The medicine must be stored out of the reach and sight of children; a locked cupboard at least 1.5 metres above the ground is advised.
Disposal Instructions	Unused or expired Deseril must not be taken and must be returned to a pharmacist for disposal or handled in accordance with local requirements.

Deseril